Arena Pharmaceuticals Inc
Arena Pharmaceuticals's GHG Emissions Data Preview
In 2020, Arena Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Arena Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Arena Pharmaceuticals's Operational Emissions
In 2020, the total operational greenhouse gas (GHG) emissions of Arena Pharmaceuticals amounted to 213 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2019, the total operational greenhouse gas (GHG) emissions of Arena Pharmaceuticals decreased by 64.14%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Arena Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Arena Pharmaceuticals's Scope 1 emissions?
In 2020, the total Scope 1 emissions of Arena Pharmaceuticals were 53 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Arena Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2018, Arena Pharmaceuticals's Scope 1 emissions have decreased by 39.08%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2019), Arena Pharmaceuticals's Scope 1 emissions decreased by 80.73%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Arena Pharmaceuticals's Scope 2 emissions?
In 2020, Arena Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 160 tCOâ‚‚e without specifying the calculation method.
Has Arena Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2018, Arena Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 41.82%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2019), Arena Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) fell by 49.84% in 2020, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.
What methodology does Arena Pharmaceuticals use for Scope 2 reporting?
In 2020, Arena Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.
Arena Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Arena Pharmaceuticals's Total Carbon Footprint
In 2020, Arena Pharmaceuticals reported a total carbon footprint of 213 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 64.14% decrease compared to 2019, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to Arena Pharmaceuticals's total carbon footprint was Scope 2 emissions, accounting for 75.12% of the company's total carbon footprint, followed by Scope 1 emissions at 24.88%.